MedTrace Logo

A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

NCT00246337 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2015-11-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.

Conditions

Interventions

DRUG

Comparator: Placebo

Placebo to match assigned treatment arm; one orally-administered dose

DRUG

MK0974

MK0974 25 mg; one orally-administered dose

DRUG

MK0974

MK0974 50 mg; one orally-administered dose

DRUG

MK0974

MK0974 100 mg; one orally-administered dose

DRUG

MK0974

MK0974 200 mg; one orally-administered dose

DRUG

MK0974

MK0974 300 mg; one orally-administered dose

DRUG

MK0974

MK0974 400 mg; one orally-administered dose

DRUG

MK0974

MK0974 600 mg; one orally-administered dose

DRUG

Rizatriptan

Rizatriptan 10 mg; one orally-administered dose

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2006-05-31
Completion
2006-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00246337 on ClinicalTrials.gov